We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
+34.9%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$123M
AUM Growth
+$21.1M
(+21%)
Cap. Flow
+$8.21M
Cap. Flow
% of AUM
6.67%
Top 10 Holdings %
Top 10 Hldgs %
62.1%
Holding
78
New
19
Increased
23
Reduced
16
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verastem
VSTM
|
+$9.75M |
| 2 |
Evolus
EOLS
|
+$4.83M |
| 3 |
OmniAb
OABI
|
+$3.92M |
| 4 |
X4 Pharmaceuticals
XFOR
|
+$2.72M |
| 5 |
Abeona Therapeutics
ABEO
|
+$2.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Indivior Pharmaceuticals
INDV
|
+$5.23M |
| 2 |
ITOS
iTeos Therapeutics
ITOS
|
+$3.09M |
| 3 |
ANI Pharmaceuticals
ANIP
|
+$2.52M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
+$2.39M |
| 5 |
Anika Therapeutics
ANIK
|
+$2.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.76% |
| 2 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Codexis
CDXS
$156M
| $215K | 0.18% |
+88,264
| New | +$241K |
|
52
Savara
SVRA
$1.09B
| $214K | 0.17% |
60,000
-25,000
| -29% | -$73.9K |
|
|
ABVX
53
Abivax
ABVX
$10.9B
| $212K | 0.17% |
+2,500
| New | +$153K |
|
54
Processa Pharmaceuticals
PCSA
$5.9M
| $198K | 0.16% |
+41,208
| New | +$218K |
|
55
Larimar Therapeutics
LRMR
$413M
| $80.8K | 0.07% |
+25,000
| New | +$93.7K |
|
|
CMMB
56
Chemomab Therapeutics
CMMB
$11.9M
| $78.9K | 0.06% |
+30,000
| New | +$111K |
|
|
WHWK
57
Whitehawk Therapeutics
WHWK
$196M
| $67K | 0.05% |
+35,253
| New | +$64.8K |
|
58
Jasper Therapeutics
JSPR
$20.2M
| $48.1K | 0.04% |
+20,200
| New | +$61.3K |
|
59
Achieve Life Sciences
ACHV
$649M
| – | – |
-333,333
| Closed | -$753K |
|
|
60
Anika Therapeutics
ANIK
$277M
| – | – |
-190,590
| Closed | -$2.02M |
|
|
61
ANI Pharmaceuticals
ANIP
$1.82B
| – | – |
-38,597
| Closed | -$2.52M |
|
62
CalciMedica
CALC
$11.9M
| – | – |
-85,000
| Closed | -$136K |
|
63
Coherus Oncology
CHRS
$222M
| – | – |
-62,700
| Closed | -$45.9K |
|
64
Collegium Pharmaceutical
COLL
$1.15B
| – | – |
-41,500
| Closed | -$1.23M |
|
65
Monte Rosa Therapeutics
GLUE
$1.3B
| – | – |
-30,000
| Closed | -$135K |
|
|
HLVX
66
DELISTED
HilleVax
HLVX
| – | – |
-226,009
| Closed | -$450K |
|
|
ITOS
67
DELISTED
iTeos Therapeutics
ITOS
| – | – |
-310,033
| Closed | -$3.09M |
|
|
KALV
68
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-100,000
| Closed | -$1.13M |
|
69
Kura Oncology
KURA
$816M
| – | – |
-25,000
| Closed | -$144K |
|
70
Liquidia Corp
LQDA
$7.46B
| – | – |
-50,000
| Closed | -$623K |
|
71
Myomo
MYO
$40.2M
| – | – |
-457,419
| Closed | -$988K |
|
72
Nuvation Bio
NUVB
$2.14B
| – | – |
-85,300
| Closed | -$166K |
|
73
Spero Therapeutics
SPRO
$66.6M
| – | – |
-156,888
| Closed | -$455K |
|
|
THTX
74
DELISTED
Theratechnologies
THTX
| – | – |
-189,051
| Closed | -$446K |
|
|
75
CALL
Verastem
VSTM
$500M
| – | – |
-100,000
| Closed | -$415K |
|
Similar funds
ER
FDDB
VM
SCM
CWM
EWM
RA
TAM
Stonepine Capital Management's Q3 2025 Portfolio in Review
As of Q3 2025, Stonepine Capital Management held 78 positions worth $123M, up 21% from $102M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Stonepine Capital Management deployed $8.21M of net new capital in Q3 2025, opening 19 new positions and adding to 23 existing holdings. Its largest new stake was OmniAb: 2,142,857 shares worth $3.43M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Indivior Pharmaceuticals, an estimated $5.23M trimmed.
- Stonepine Capital Management's largest Q3 2025 buy was OmniAb: 2,142,857 shares worth $3.43M.
- Stonepine Capital Management added most to Verastem in Q3 2025, an estimated $9.75M increase.
- Stonepine Capital Management's biggest Q3 2025 reduction was Indivior Pharmaceuticals, cutting an estimated $5.23M.
- Stonepine Capital Management fully exited iTeos Therapeutics in Q3 2025, selling an estimated $3.09M.
- Stonepine Capital Management's ten largest holdings make up 62% of its $123M portfolio in Q3 2025.
- Stonepine Capital Management opened 19 new positions and closed 20 in Q3 2025.
- Stonepine Capital Management's portfolio value rose 21% quarter-over-quarter to $123M.
Based on Stonepine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.